204 related articles for article (PubMed ID: 11913520)
1. Antiparkinsonian drugs and their neuroprotective effects.
Kitamura Y; Kakimura J; Taniguchi T
Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
[TBL] [Abstract][Full Text] [Related]
3. The parkinsonian models: invertebrates to mammals.
Kitamura Y; Shimohama S; Akaike A; Taniguchi T
Jpn J Pharmacol; 2000 Nov; 84(3):237-43. PubMed ID: 11138723
[TBL] [Abstract][Full Text] [Related]
4. Prospects for new restorative and neuroprotective treatments in Parkinson's disease.
Dunnett SB; Björklund A
Nature; 1999 Jun; 399(6738 Suppl):A32-9. PubMed ID: 10392578
[TBL] [Abstract][Full Text] [Related]
5. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
Elife; 2021 Sep; 10():. PubMed ID: 34550070
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
7. New movement in Parkinson's.
Lozano AM; Kalia SK
Sci Am; 2005 Jul; 293(1):68-75. PubMed ID: 16008304
[No Abstract] [Full Text] [Related]
8. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
9. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
10. Possible neuroprotective therapy for Parkinson's disease.
Ogawa N
Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
[TBL] [Abstract][Full Text] [Related]
11. Rationale for dopamine agonist use as monotherapy in Parkinson's disease.
Schwarz J
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S27-33. PubMed ID: 15180135
[TBL] [Abstract][Full Text] [Related]
12. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Le WD; Jankovic J
Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
[TBL] [Abstract][Full Text] [Related]
13. Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Abdin AA; Sarhan NI
Neurosci Res; 2011 Dec; 71(4):387-95. PubMed ID: 21889550
[TBL] [Abstract][Full Text] [Related]
14. [Future drug targets for Parkinson's disease].
Hirsch EC
Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
[TBL] [Abstract][Full Text] [Related]
15. Disease modification in Parkinson's disease.
Schapira AH
Lancet Neurol; 2004 Jun; 3(6):362-8. PubMed ID: 15157851
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
Morgan AH; Rees DJ; Andrews ZB; Davies JS
Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
[TBL] [Abstract][Full Text] [Related]
17. Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
Ziv I; Offen D; Barzilai A; Haviv R; Stein R; Zilkha-Falb R; Shirvan A; Melamed E
J Neural Transm Suppl; 1997; 49():195-202. PubMed ID: 9266428
[TBL] [Abstract][Full Text] [Related]
18. Modulation of endoplasmic reticulum stress in Parkinson's disease.
Tsujii S; Ishisaka M; Hara H
Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: new drugs in development for Parkinson's disease.
Colosimo C; Fabbrini G; Berardelli A
Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
